15th International Workshop on Clinical Pharmacology of HIV and Hepatitis Therapy, May 19- 21, 2014, Washington, DC

Conference Reports for NATAP


15th International Workshop on Clinical Pharmacology of HIV and Hepatitis Therapy May 19- 21, 2014, Washington, DC

	Abstract Book Clin Pharm Wk 2014 - (03/16/14) A novel microdose approach to assess bioavailability, intestinal absorption, gut metabolism, and hepatic clearance of simeprevir in healthy volunteers - (06/16/14) PBPK modeling to characterize the interplay between metabolism and transport in the disposition of simeprevir in healthy volunteers and HCV infected patients - (06/16/14) Antiviral Quantification in Paired Blood and Liver Tissue or Hepatocytes - (06/11/14) The 15th International Workshop on Clinical Pharmacology of HIV and Hepatitis Therapy - written by Courtney V. Fletcher, Pharm.D. Dean and Professor College of Pharmacy University of Nebraska Medical Center Jennifer J. Kiser, Pharm.D. Assistant Professor School of Pharmacy University of Colorado at Denver - (06/11/14) Week 48 pharmacokinetic and pharmacodynamic results of darunavir 800mg once daily when co-administered with cobicistat 150mg once daily in HIV-1-infected patients with no darunavir resistance-associated mutations: GS-US-216-0130 - (06/11/14) Rectal Tenofovir Gel Yields Much Higher Rectal and Vaginal Levels Than Oral Tenofovir - (05/29/14) Pharmacokinetics and Safety of Tenofovir Alafenamide in Subjects With Mild or Moderate Hepatic Impairment - (05/29/14) Pharmacokinetics and Safety of Tenofovir Alafenamide in Subjects With Mild or Moderate Hepatic Impairment - (05/29/14) Bristol-Myers Squibb HCV DAAs: Review of Interactions Involving Transporters - (05/28/14) DDIs (drug-drug interactions) in the evolving HCV treatment landscape - (05/28/14) Raltegravir Levels With Once-Daily Dosing in French Observational Study - Mark Mascolini - (05/27/14) Pharmacokinetics and Safety of Hepatitis C Virus Nonstructural Protein 5A Inhibitor MK-8742 in Cirrhotic Patients With Mild and Moderate Hepatic Insufficiency - (05/27/14) Pharmacokinetics of Hepatitis C Virus Protease Inhibitor MK-5172 in Volunteers With Mild and Moderate Hepatic Impairment - (05/27/14) Age and Gender Effects on the Pharmacokinetics of HCV NS5A Inhibitor MK-8742 - (05/27/14) Pharmacokinetic Interaction of HCV NA5A Inhibitor MK-8742 and Ketoconazole in Healthy Subjects - (05/27/14) Effect of Food and Acid Reducing Agents on the Relative Bioavailability and Pharmacokinetics of Ledipasvir/Sofosbuvir Fixed-Dose Combination Tablet - (05/27/14) Population Pharmacokinetic Analysis of Ledipasvir (GS-5885) in Healthy and Hepatitis C Virus-Infected Subjects - (05/27/14) Evaluation of the Effect of Ledipasvir on the QT/QTc Interval in Healthy Subjects - (05/27/14) Drug Interactions Between Direct-Acting anti-HCV Antivirals Sofosbuvir and Ledipasvir and HIV Antiretrovirals - (05/27/14) Evaluation of Transporter and Cytochrome P450-Mediated Drug-Drug Interactions Between Pan-Genotypic HCV NS5A Inhibitor GS-5816 and Phenotypic Probe Drugs - Mark Mascolini - (05/23/14) The Effect of Steady-state BMS-791325, a Non-nucleoside HCV NS5B Polymerase Inhibitor, on the Pharmacokinetics of Midazolam in Healthy Japanese and Caucasian Males - (05/23/14) Assessment of Correlation of Asunaprevir With Polymorphisms in Liver Uptake Transporters (OATP1B1 and 2B1): Results of an Integrated Population PK Analyses - (05/23/14) Asunaprevir Does Not Have an Effect on QTcF Interval in Healthy Subjects - (05/23/14) Resistance Analysis in Patients Receiving Daclatasvir in Combination With Asunaprevir and BMS-791325: Hepatitis C Virus Genotype 1 Infection - (05/23/14) No Clinically Meaningful Effect of Single- and Multiple-Dose Administration of Peginterferon Lambda-1a on the QTc Interval - (05/23/14) Translational Studies to Understand the Mechanism of Liver Delivery by Sofosbuvir - (05/23/14) Gilead - Transporters: Role in Clinical Development of HCV Compounds - (05/23/14) Unbound Darunavir Above Wild-Type EC50 With Once-Daily Dose in Pregnancy - Mark Mascolini - (05/23/14) DRV CONCENTRATIONS AND VIRAL LOAD IN CSF OF PATIENTS ON DRV/r 600/100 OR 800/100 mg ONCE DAILY, PLUS TWO NRTI - (05/23/14) Thorough QT/QTc Trial to Evaluate the Effect of the HIV-1 Attachment Inhibitor BMS-626529, Administered as its Prodrug, BMS-663068, on QTc Intervals - (05/23/14) Clinically Relevant Interactions Between GS5816 HCV NS5A Inhibitor and Probe Drugs - Mark Mascolini - (05/22/14) A Mechanistic SimCYP Simulation Evaluating Dolutegravir and Efavirenz Pharmacokinetics Following a Switch From Once-daily Efavirenz to Once-daily Dolutegravir - (05/22/14) A multi-compartment single and multiple dose pharmacokinetic comparison of rectally applied tenofovir 1% gel and oral tenofovir disoproxil fumarate - (05/22/14) Maraviroc and Raltegravir Quickly Distributed in Female Genital Tract - Mark Mascolini (05/22/14) Unbound Darunavir Above Wild-Type EC50 With Once-Daily Dose in Pregnancy - Mark Mascolini - (05/22/14) PHARMACOKINETICS OF SIMEPREVIR, JNJ-56914845 AND RITONAVIR-BOOSTED TMC647055 WHEN CO-ADMINISTERED IN HEALTHY VOLUNTEERS - (05/22/14) The Effect of Renal Impairment on Single-Dose Pharmacokinetics of Daclatasvir, an HCV NS5A Inhibitor - (05/22/14) Drug Interactions Between Direct-Acting anti-HCV Antivirals Sofosbuvir and Ledipasvir and HIV Antiretrovirals - (05/22/14) ABT-450/Ritonavir +Ombitasvir + Dasabuvir: Drug Interactions Mediated by Transporters - (05/21/14) Pharmacokinetic of raltegravir (800 mg) once-daily in switching strategies in HIV-1-infected patients with suppressed viremia - (05/21/14) No Critical Interactions Between Ledipasvir/Sofosbuvir and Certain Key Antiretrovirals - written by Mark Mascolini - (05/21/14) Pharmacokinetics and Safety of IDX21437, a Novel HCV Nucleotide Prodrug, in Healthy Volunteers and HCV-Infected Subjects: Results of a First-In-Human Study - (05/21/14) Idenix IDX437/IDX719 Development Program - (05/21/14) Mucosal Tissue Pharmacokinetics of Maraviroc and Raltegravir in Women: Implications for Chemoprophylaxis [PrEP, Mucosal Tissue Compartments PK] - (05/21/14) Reduced Darunavir Dose Is as Effective in Maintaining HIV Suppression as the Standard Dose in Virologically Suppressed HIV-Infected Patients. The DRV600 Study - (05/21/14) In Vitro Drug Interaction Profile of the HIV Integrase Inhibitor, GSK1265744, and Demonstrated Lack of Clinical Interaction with Midazolam - (05/21/14) The Effect of Calcium and Iron Supplements on the Pharmacokinetics of Dolutegravir in Healthy Subjects - (05/21/14) Population PK-PD Analysis of 400 mg vs. 600 mg Efavirenz Once Daily in Treatment-Naïve HIV Patients at 48 Weeks: Results of the ENCORE1 Study - (05/21/14) No Critical Interactions Between Ledipasvir/Sofosbuvir and Certain Key Antiretrovirals - written by Mark Mascolini - (05/21/14) Estimated Time to Protection and Duration of Protection With Daily TDF/FTC PrEP - written by Mark Mascolini - (05/21/14) Impact of Food and Antacids on Levels of Ledipasvir and Sofosbuvir - written by Mark Mascolini - (05/20/14) Maintenance With Lower-Dose Darunavir in Virologically Suppressed - written by Mark Mascolini - (05/20/14) Efavirenz Dose and Genotype Do Not Affect 48-Week Response in Low/Standard-Dose Trial - written by Mark Mascolini - (05/20/14) Calcium and Iron Supplements Lower Dolutegravir Levels When Taken Between Meals - written by Mark Mascolini - (05/20/14)